SCHEMBL2167367

SCHEMBL2167367

[CH2]/C=C/COc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.61
KCNA3 P22001 1/20 0.46
TAAR1 Q96RJ0 1/20 0.41
ALDH1A1 P00352 1/20 0.41
RECQL P46063 1/20 0.41
ALOX15 P16050 1/20 0.40
THRB P10828 1/20 0.39
LTA4H P09960 1/20 0.39
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
KCNH2 Q12809 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2167369 1.00 AOC3 (0.61) AOC3KCNA3TAAR1ALDH1A1RECQL
SCHEMBL419306 0.85 AOC3 (0.78) AOC3KCNA3TAAR1ALDH1A1RECQL
SCHEMBL419305 0.85 AOC3 (0.78) AOC3KCNA3TAAR1ALDH1A1RECQL
SCHEMBL8526568 0.81 AOC3 (0.54) AOC3KCNA3TAAR1ALDH1A1RECQL
SCHEMBL10607106 0.78 AOC3 (0.57) AOC3KCNA3TAAR1ALDH1A1RECQL
SCHEMBL10903565 0.78 CA12 (0.46) AOC3ALDH1A1ALOX15CYP2C9MAOB
SCHEMBL10348527 0.78 MAOB (0.40) AOC3KCNH2DRD2DRD4DRD3
SCHEMBL10905751 0.78 MAOB (0.40) AOC3KCNH2DRD2DRD4DRD3
SCHEMBL11515864 0.78 MAOB (0.41) AOC3DRD2DRD4DRD3CYP2C19
SCHEMBL9064304 0.78 AGXT (0.53) KCNH2DRD3LMNAMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1970368-B1 METHOD FOR PRODUCING OLEFIN COMPOUND SUMITOMO CHEMICAL CO (JP) 2012-08-29 EP disclosed
US-7985872-B2 Method for producing olefin compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-07-26 US disclosed
US-7700799-B2 Method for producing (2-formyl-1-alkenyl) cyclopropane compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-20 US disclosed
US-20090137839-A1 METHOD FOR PRODUCING (2-FORMYL-1-ALKENYL) CYCLOPROPANE COMPOUND SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2009-05-28 US disclosed
US-7498459-B2 Method for producing (1-alkenyl)cyclopropane compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-03 US disclosed
US-20090036620-A1 METHOD FOR PRODUCING OLEFIN COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-02-05 US disclosed
EP-1970368-A1 METHOD FOR PRODUCING OLEFIN COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-09-17 EP disclosed
US-20070197818-A1 Method for producing (1-alkenyl) cyclopropane compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-08-23 US disclosed
EP-1728781-A1 PROCESS FOR PRODUCTION OF (1-ALKENYL)CYCLOPROPANES Sumitomo Chemical Company, Limited (JP) 2006-12-06 EP disclosed
EP-1699763-A1 3-TRIFLUOROMETHYL PICOLINIC ACID ANILIDES, AND USE THEREOF AS FUNGICIDES BASF AKTIENGESELLSCHAFT (DE) 2006-09-13 EP disclosed
WO-2005063710-A1 3-TRIFLUOROMETHYL PICOLINIC ACID ANILIDES, AND USE THEREOF AS FUNGICIDES BASF AKTIENGESELLSCHAFT (DE) 2005-07-14 WO disclosed
US-6323235-B1 CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS AND ENZYME INHIBITORS OHTAKE ATSUSHI (JP) 2001-11-27 US disclosed
US-6043264-A A THROMBOXANE A2 RECEPTOR ANTAGONIST FOR TREATING HYPERTENSION, THROMBOSIS, ISCHEMIC HEART DISEASES, CIRCULATORY DISEASES, ARTERIOSCLEROSIS, PLATELET FUNCTION DISORDER, HYPERLIPIDEMIA, NEPHRITIS OR ASTHMA TORAY INDUSTRIES, INC. (JP) 2000-03-28 US disclosed
EP-0751126-A1 BENZENE-FUSED HETEROCYCLIC DERIVATIVE AND USE OF THE SAME TORAY INDUSTRIES, INC. (JP) 1997-01-02 EP disclosed
EP-0733364-A1 MEDICINAL COMPOSITION FOR CIRCULATORY ORGAN NIPPON SHINYAKU COMPANY, LIMITED (JP) 1996-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137839-A1 METHOD FOR PRODUCING (2-FORMYL-1-ALKENYL) CYCLOPROPANE COMPOUND ACSL3, ACSL1, ARL1 AOC3 147/4885KCNA3 4074/4885TAAR1 698/4885
US-20070197818-A1 Method for producing (1-alkenyl) cyclopropane compound ACSL3, ARL1, ACSL1 AOC3 162/4885KCNA3 3542/4885TAAR1 1072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.